Evommune Halts EVO756 in Atopic Dermatitis After Phase 2b Failure; Cash Runway Extended to 2029
EVMN is trading near its 52-week low of $10.47 (4.0% above the low).
Summary
Evommune's lead drug EVO756 failed a Phase 2b atopic dermatitis trial, prompting the company to halt development in that indication. Cash runway guidance was extended to 2029 as the company pivots to migraine prophylaxis.
Key Events · Product Development and Regulatory · EVMN
-
EVO756 Fails Phase 2b in Atopic Dermatitis
The 121-patient trial missed primary and secondary endpoints across all doses studied, leading Evommune to cease development of EVO756 for AD.
-
Second Pipeline Setback in Three Months
This follows the June 2026 failure of EVO756 in chronic spontaneous urticaria, leaving migraine prophylaxis as the sole remaining indication for the lead asset.
-
Cash Runway Extended to 2029
Management now expects current cash to fund operations into 2029, up from the prior 2028 guidance, reflecting reduced spending after halting the AD program.
-
Stock Near 52-Week Low
Shares closed at $13.08 on September 8, 2026, and are trading near the 52-week low of $10.47, reflecting investor concern about the pipeline's viability.
Analysis · EVMN · Life Sciences
EVO756 missed primary and secondary endpoints in a 121-patient Phase 2b atopic dermatitis trial, and Evommune is ceasing development in that indication. This is the second major setback for the drug in three months, following the June failure in chronic spontaneous urticaria. The company is now betting its future on migraine prophylaxis, a much earlier-stage program. The one bright spot: management says current cash will now fund operations into 2029, up from the prior 2028 guidance, suggesting the AD program was a significant cost driver. The stock is trading near its 52-week low, reflecting the market's loss of confidence in the lead asset.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 42.6% of the 523 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVMN was trading at $10.89 on NYSE in the Life Sciences sector, with a market capitalization of approximately $474.7M. The 52-week trading range was $10.47 to $33.20. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.